Neutrophil gelatinase-associated lipocalin and liver-type fatty acid-binding protein as biomarkers for acute kidney injury after organ transplantation.

Abstract

Neutrophil gelatinase-associated lipocalin (NGAL) and liver-type fatty acid-binding protein (L-FABP) are promising early biomarkers for acute kidney injury (AKI). In organ transplant recipients, AKI predictability based on NGAL and L-FABP remains to be elucidated. Furthermore, the association between serial NGAL and L-FABP measurements and AKI outcome is unknown. Therefore, we conducted a study to evaluate the ability of NGAL and L-FABP to predict AKI after organ transplantation and investigate the association between NGAL, L-FABP and AKI outcome. Twenty-five organ transplant recipients admitted to the intensive care unit (ICU) immediately after transplant surgery were studied prospectively. Plasma NGAL (P-NGAL), urinary NGAL (U-NGAL) and L-FABP were measured from ICU admission to ICU discharge. U-NGAL and L-FABP were corrected for dilution/concentration by calculating U-NGAL/urine creatinine ratios (U-NGAL/Cr) and L-FABP/urine creatinine ratios (L-FABP/Cr). AKI was defined according to the Kidney Disease: Improving Global Outcomes criteria. AKI occurred in 11 patients. P-NGAL, U-NGAL/Cr and L-FABP/Cr upon ICU admission were unrelated to AKI development (p=0.24, 0.22, and 0.53, respectively). There were no differences in P-NGAL, U-NGAL/Cr, and L-FABP/Cr levels from day 1 to day 6 between patients who did not recover from AKI and patients who recovered from AKI (p=0.82, 0.26, and 0.61, respectively). Our findings suggest that NGAL and L-FABP upon ICU admission are not predictive of AKI and serial NGAL and L-FABP measurements may be ineffective for monitoring the status and treatment of post-transplantation AKI.